NOV 1 & 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

hoto aly Per

November 10, 2003

Vette Alvarez-Perez

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/621,590

Applicant

: Peter Emig

Filed

: July 17, 2003

Title

: New Anthracene Derivatives and Their Use as Pharmaceutical Preparations

Docket No.

: 103832-434-NP

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant brings to the attention of the Examiner the documents listed on the attached PTO/SB/08 (substitute for form 1449/PTO). Copies of the listed documents are enclosed. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This Information Disclosure Statement is being filed before the mailing of a first office action, and therefore no fee is necessary. However, the Commissioner is still authorized to charge the required fees, if any, to Deposit Account 06-0923.

Respectfully submitted,

Eva Tan (Reg. No. 46,406)

Goodwin Procter LLP

103 Eisenhower Parkway

Roseland, NJ 07068

(973) 992-1990 Ext. 7904

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known			
Application Number	10/621.590		
Filing Date	July 17, 2003		
First Named Inventor	Peter Emig		
Art Unit			
Examiner Name			
Attornov Docket Number	103832-434-NID		

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 103832-434-NP

	U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	^{US-} 5.110.927	05/05/1992	Josef Pitha et al.			
		US-			. ,		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			11 11 - 111 		
		US-	····				
		US-					
		US-					
		US-		· · · · · · · · · · · · · · · · · · ·			
		US-					
		US-					
· 		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
minais	NO.	Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	<u> </u>
	2	WO 02/08194 A1	01/31/2002	ZENTARIS AG		
	3	WO 02/08192 A1	01/31/2002	ZENTARIS AG		
	4 ·	WO 97/14685 A1	04/24/1997			
	5	WO 00/59930 A1	10/12/2000	MERCK & CO., INC.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
for the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7	Substitute fo	or form 1449B/PTO				Complete if Known	
					Application Number	10/621,590	
	INFO	RMATION DI	SCLO	SURE	Filing Date	July 17, 2003	
	STATEMENT BY APPLICANT			CANT	First Named Inventor	Peter Emig	
					Art Unit		
		(Use as many sheets as	necessary)	Examiner Name	<u> </u>	"
	Sheet	2	of	2	Attorney Docket Number	103832-434-NP	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	6	EBCID M Y ET AL: "SYNTHESIS AND ANTITUMOR ACTIVITY OF SOME 4 - {4 - [4 - (2-HYDROXYETTHYL)PIPERAZINE-1-CARBON YL] ACRIDIN -9-YLAMINO)BENZENESULFONAMIDE DERIVTIVES" BULLETIN OF THE FACULTY OF PHARMACY (CAIRO UNIVERSITY), XX, XX, Bd. 32, Nr. 3, 1994, Seiten 361-368, XP001037725 Beispiele 7-10	
	7	ATWEEL G J ET AL: "POTENTIAL ANTITUMOR AGENTS. 50. IN VIVO SOLID-TUMOR ACTIVITY OF DERIVATIVES OF N-[2-(DIMETHYLAMINO) ethyl]ACRIDINE-4-CARBOXAMIDE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, Bd. 30, Nr. 4, 1987, Seiten 664-669, XP002051603 ISSN: 0022-2623 Beispiele; Tablee 1	
	8	Romero et al. J. Med. Chem. 37,999 (1994)	
	***************************************	-	••••
•••••			••••
•••••			••••
			••••

••••			•••••
•••••			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.